Patents by Inventor Sirid-Aimee Kellermann
Sirid-Aimee Kellermann has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20100197005Abstract: The present invention relates to antibodies including human antibodies and antigen-binding portions thereof that bind to the extracellular domain (ECD) of activin receptor-like kinase-1 (ALK-1) and that function to abrogate the ALK-1/TGF-beta-1/Smad1 signaling pathway. The invention also relates to heavy and light chain immunoglobulins derived from human anti-ALK-1 antibodies and nucleic acid molecules encoding such immunoglobulins. The present invention also relates to methods of making human anti-ALK-1 antibodies, compositions comprising these antibodies and methods of using the antibodies and compositions. The invention also relates to transgenic animals or plants comprising nucleic acid molecules of the present invention.Type: ApplicationFiled: March 12, 2009Publication date: August 5, 2010Applicants: Amgen Fremont Inc., Pfizer Inc.Inventors: Shelley Sims Belouski, Sirid-Aimee Kellermann, Michael Aidan North, Karin Kristina Amundson, Vahe Bedian, Dana Dan Hu-Lowe, Xin Jiang, Shannon Marie Karlicek, James Arthur Thomson, Jianying Wang, Grant Raymond Wickman, Jingchuan Zhang
-
Patent number: 7728113Abstract: The present invention relates to antibodies and antigen-binding portions thereof that specifically bind to a M-CSF, preferably human M-CSF, and that function to inhibit a M-CSF. The invention also relates to human anti-M-CSF antibodies and antigen-binding portions thereof. The invention also relates to antibodies that are chimeric, bispecific, derivatized, single chain antibodies or portions of fusion proteins. The invention also relates to isolated heavy and light chain immunoglobulins derived from human anti-M-CSF antibodies and nucleic acid molecules encoding such immunoglobulins. The present invention also relates to methods of making human anti-M-CSF antibodies, compositions comprising these antibodies and methods of using the antibodies and compositions for diagnosis and treatment. The invention also provides gene therapy methods using nucleic acid molecules encoding the heavy and/or light immunoglobulin molecules that comprise the human anti-M-CSF antibodies.Type: GrantFiled: August 20, 2007Date of Patent: June 1, 2010Assignees: Amgen Fremont Inc., Warner-Lambert Company LLCInventors: Vahe Bedian, Madhav Narasimha Devalaraja, Ian Foltz, Mary Haak-Frendscho, Sirid-Aimée Kellermann, Joseph Edwin Low, James Leslie Mobley
-
Publication number: 20100028906Abstract: The present embodiments relate to methods of identifying and creating human or humanized antibodies that possess a reduced risk of inducing a Human Anti-Human Antibody (HAHA) response when they are applied to a human host. Other methods are directed to predicting the likelihood of a HAHA response occurring. Methods for screening for anti-HAHA compounds are also included. Methods for determining if various conditions for administering an antibody to a subject enhance or suppress a HAHA response are also included.Type: ApplicationFiled: October 12, 2009Publication date: February 4, 2010Applicant: AMGEN FREMONT INC.Inventors: Sirid-Aimee Kellermann, Larry L. Green, Wouter Korver
-
Patent number: 7625549Abstract: The present embodiments relate to methods of identifying and creating human or humanized antibodies that possess a reduced risk of inducing a Human Anti-Human Antibody (HAHA) response when they are applied to a human host. Other methods are directed to predicting the likelihood of a HAHA response occurring. Methods for screening for anti-HAHA compounds are also included. Methods for determining if various conditions for administering an antibody to a subject enhance or suppress a HAHA response are also included.Type: GrantFiled: May 23, 2005Date of Patent: December 1, 2009Assignee: Amgen Fremont Inc.Inventors: Sirid-Aimée Kellermann, Larry L. Green, Wouter Korver
-
Patent number: 7592430Abstract: The present invention relates to antibodies and antigen-binding portions thereof that specifically bind to a M-CSF, preferably human M-CSF, and that function to inhibit a M-CSF. The invention also relates to human anti-M-CSF antibodies and antigen-binding portions thereof. The invention also relates to antibodies that are chimeric, bispecific, derivatized, single chain antibodies or portions of fusion proteins. The invention also relates to isolated heavy and light chain immunoglobulins derived from human anti-M-CSF antibodies and nucleic acid molecules encoding such immunoglobulins. The present invention also relates to methods of making human anti-M-CSF antibodies, compositions comprising these antibodies and methods of using the antibodies and compositions for diagnosis and treatment. The invention also provides gene therapy methods using nucleic acid molecules encoding the heavy and/or light immunoglobulin molecules that comprise the human anti-M-CSF antibodies.Type: GrantFiled: September 9, 2004Date of Patent: September 22, 2009Assignees: Amgen Fremont, Warner-Lambert Company, LLCInventors: Vahe Bedian, Madhav Narasimha Devalaraja, Ian Foltz, Mary Haak-Frendscho, Sirid-Aimée Kellermann, Joseph Edwin Low, James Leslie Mobley
-
Publication number: 20090117124Abstract: The present invention relates to novel human antibodies specifically directed against human immunoglobulin E (anti-IgE). The present invention also relates to pharmaceutical compositions and methods for treating asthma, in particular allergic asthma, as well as other IgE-mediated disorders including allergic rhinitis and food allergies.Type: ApplicationFiled: April 1, 2008Publication date: May 7, 2009Inventors: Wai Liu, Mike Yeadon, Isabelle de Mendez, Alison Logan, Gerald F. Casperson, Arvind Rajpal, Mark A. Moffat, Wei Liao, Caroline Brown, Nurten Beyaz-Kavuncu, Judith Diaz-Collier, Sirid-Aimee Kellermann
-
Publication number: 20080254032Abstract: The present invention relates to antibodies and antigen-binding portions thereof that specifically bind to a M-CSF, preferably human M-CSF, and that function to inhibit a M-CSF. The invention also relates to human anti-M-CSF antibodies and antigen-binding portions thereof. The invention also relates to antibodies that are chimeric, bispecific, derivatized, single chain antibodies or portions of fusion proteins. The invention also relates to isolated heavy and light chain immunoglobulins derived from human anti-M-CSF antibodies and nucleic acid molecules encoding such immunoglobulins. The present invention also relates to methods of making human anti-M-CSF antibodies, compositions comprising these antibodies and methods of using the antibodies and compositions for diagnosis and treatment. The invention also provides gene therapy methods using nucleic acid molecules encoding the heavy and/or light immunoglobulin molecules that comprise the human anti-M-CSF antibodies.Type: ApplicationFiled: August 20, 2007Publication date: October 16, 2008Applicants: Abgenix, Inc., Warner-Lambert Company LLCInventors: Vahe Bedian, Madhav Narasimha Devalaraja, Ian Foltz, Mary Haak-Frendscho, Sirid-Aimee Kellermann, Joseph Edwin Low, James Leslie Mobley
-
Publication number: 20080124339Abstract: The present invention relates to antibodies including human antibodies and antigen-binding portions thereof that specifically bind to MAdCAM, preferably human MAdCAM and that function to inhibit MAdCAM. The invention also relates to human anti-MAdCAM antibodies and antigen-binding portions thereof. The invention also relates to antibodies that are chimeric, bispecific, derivatized, single chain antibodies or portions of fusion proteins. The invention also relates to isolated heavy and light chain immunoglobulins derived from human anti-MAdCAM antibodies and nucleic acid molecules encoding such immunoglobulins. The present invention also relates to methods of making human anti-MAdCAM antibodies, compositions comprising these antibodies and methods of using the antibodies and compositions for diagnosis and treatment. The invention also provides gene therapy methods using nucleic acid molecules encoding the heavy and/or light immunoglobulin molecules that comprise the human anti-MAdCAM antibodies.Type: ApplicationFiled: August 20, 2007Publication date: May 29, 2008Inventors: Nicholas Pullen, Elizabeth Molloy, Sirid-Aimee Kellermann, Larry L. Green, Mary Haak-Frendscho
-
Patent number: 7326414Abstract: The present invention relates to antibodies and antigen-binding portions thereof that specifically bind to a M-CSF, preferably human M-CSF, and that function to inhibit a M-CSF. The invention also relates to human anti-M-CSF antibodies and antigen-binding portions thereof. The invention also relates to antibodies that are chimeric, bispecific, derivatized, single chain antibodies or portions of fusion proteins. The invention also relates to isolated heavy and light chain immunoglobulins derived from human anti-M-CSF antibodies and nucleic acid molecules encoding such immunoglobulins. The present invention also relates to methods of making human anti-M-CSF antibodies, compositions comprising these antibodies and methods of using the antibodies and compositions for diagnosis and treatment. The invention also provides gene therapy methods using nucleic acid molecules encoding the heavy and/or light immunoglobulin molecules that comprise the human anti-M-CSF antibodies.Type: GrantFiled: March 13, 2006Date of Patent: February 5, 2008Assignees: Warner-Lambert Company LLC, Abgenix, Inc.Inventors: Vahe Bedian, Madhav Narasimha Devalaraja, Ian Foltz, Mary Haak-Frendscho, Sirid-Aimée Kellermann, Joseph Edwin Low, James Leslie Mobley
-
Publication number: 20070166308Abstract: The present invention relates to antibodies including human antibodies and antigen-binding portions thereof that specifically bind to MAdCAM, preferably human MAdCAM and that function to inhibit MAdCAM. The invention also relates to human anti-MAdCAM antibodies and antigen-binding portions thereof. The invention also relates to antibodies that are chimeric, bispecific, derivatized, single chain antibodies or portions of fusion proteins. The invention also relates to isolated heavy and light chain immunoglobulins derived from human anti-MAdCAM antibodies and nucleic acid molecules encoding such immunoglobulins. The present invention also relates to methods of making human anti-MAdCAM antibodies, compositions comprising these antibodies and methods of using the antibodies and compositions for diagnosis and treatment. The invention also provides gene therapy methods using nucleic acid molecules encoding the heavy and/or light immunoglobulin molecules that comprise the human anti-MAdCAM antibodies.Type: ApplicationFiled: July 10, 2006Publication date: July 19, 2007Inventors: Nicholas Pullen, Elizabeth Molloy, Sirid-Aimee Kellermann, Larry Green, Mary Haak-Frendscho
-
Publication number: 20060286112Abstract: The present invention relates to antibodies directed to very late antigen-1 (“VLA-1”) and uses of such antibodies. For example human monoclonal antibodies directed to VLA-1 are described. Isolated polynucleotide sequences encoding, and amino acid sequences comprising, heavy and light chain immunoglobulin molecules, particularly sequences corresponding to contiguous heavy and light chain sequences spanning the framework regions (FR's) and/or complementarity determining regions (CDR's), are provided. Hybridomas or other cell lines expressing such immunoglobulin molecules and monoclonal antibodies are also provided.Type: ApplicationFiled: May 12, 2006Publication date: December 21, 2006Inventors: Sirid-Aimee Kellermann, Orit Foord, Shelley Belouski, Larry Green
-
Publication number: 20060153850Abstract: The present invention relates to antibodies and antigen-binding portions thereof that specifically bind to a M-CSF, preferably human M-CSF, and that function to inhibit a M-CSF. The invention also relates to human anti-M-CSF antibodies and antigen-binding portions thereof. The invention also relates to antibodies that are chimeric, bispecific, derivatized, single chain antibodies or portions of fusion proteins. The invention also relates to isolated heavy and light chain immunoglobulins derived from human anti-M-CSF antibodies and nucleic acid molecules encoding such immunoglobulins. The present invention also relates to methods of making human anti-M-CSF antibodies, compositions comprising these antibodies and methods of using the antibodies and compositions for diagnosis and treatment. The invention also provides gene therapy methods using nucleic acid molecules encoding the heavy and/or light immunoglobulin molecules that comprise the human anti-M-CSF antibodies.Type: ApplicationFiled: March 13, 2006Publication date: July 13, 2006Applicants: Abgenix, Inc., Warner-Lambert Company LLCInventors: Vahe Bedian, Madhav Devalaraja, Ian Foltz, Mary Haak-Frendscho, Sirid-Aimee Kellermann, Joseph Low, James Mobley
-
Publication number: 20060002929Abstract: Nucleotide sequences encoding, and amino acid sequences comprising, heavy and light chains of monoclonal antibodies.Type: ApplicationFiled: March 23, 2005Publication date: January 5, 2006Inventors: Sanjay Khare, Sirid-Aimee Kellermann
-
Publication number: 20050232917Abstract: The present invention relates to antibodies including human antibodies and antigen-binding portions thereof that specifically bind to MAdCAM, preferably human MAdCAM and that function to inhibit MAdCAM. The invention also relates to human anti-MAdCAM antibodies and antigen-binding portions thereof. The invention also relates to antibodies that are chimeric, bispecific, derivatized, single chain antibodies or portions of fusion proteins. The invention also relates to isolated heavy and light chain immunoglobulins derived from human anti-MAdCAM antibodies and nucleic acid molecules encoding such immunoglobulins. The present invention also relates to methods of making human anti-MAdCAM antibodies, compositions comprising these antibodies and methods of using the antibodies and compositions for diagnosis and treatment. The invention also provides gene therapy methods using nucleic acid molecules encoding the heavy and/or light immunoglobulin molecules that comprise the human anti-MAdCAM antibodies.Type: ApplicationFiled: January 7, 2005Publication date: October 20, 2005Inventors: Nicholas Pullen, Elizabeth Molloy, Sirid-Aimee Kellermann, Larry Green, Mary Haak-Frendscho
-
Publication number: 20050059113Abstract: The present invention relates to antibodies and antigen-binding portions thereof that specifically bind to a M-CSF, preferably human M-CSF, and that function to inhibit a M-CSF. The invention also relates to human anti-M-CSF antibodies and antigen-binding portions thereof. The invention also relates to antibodies that are chimeric, bispecific, derivatized, single chain antibodies or portions of fusion proteins. The invention also relates to isolated heavy and light chain immunoglobulins derived from human anti-M-CSF antibodies and nucleic acid molecules encoding such immunoglobulins. The present invention also relates to methods of making human anti-M-CSF antibodies, compositions comprising these antibodies and methods of using the antibodies and compositions for diagnosis and treatment. The invention also provides gene therapy methods using nucleic acid molecules encoding the heavy and/or light immunoglobulin molecules that comprise the human anti-M-CSF antibodies.Type: ApplicationFiled: September 9, 2004Publication date: March 17, 2005Inventors: Vahe Bedian, Madhav Devalaraja, Ian Foltz, Mary Haak-Frendscho, Sirid-Aimee Kellermann, Joseph Low, James Mobley
-
Patent number: 6824781Abstract: Agonists or antagonists of CTACK or Vic chemokines, and various methods of use in dermatological and related applications are provided. In particular, the method makes use of fact that the CTACK or Vic chemokines are specifically capable of inducing movement of a skin cell subset. Moreover, matching of ligand with GPR2 receptor in mammals provides methods of use.Type: GrantFiled: July 2, 2001Date of Patent: November 30, 2004Assignee: Schering CorporationInventors: Wei Wang, Elizabeth R. Oldham, Hortensia Soto, Ying Liu, Susan A. Hudak, Bernhard Homey, Janine M. Morales, Sirid-Aimee Kellermann, Leslie M. McEvoy, Edward P. Bowman, Albert Zlotnik
-
Publication number: 20020160024Abstract: Agonists or antagonists of CTACK or Vic chemokines, and various methods of use in dermatological and related applications are provided. In particular, the method makes use of fact that the CTACK or Vic chemokines are specifically capable of inducing movement of a skin cell subset. Moreover, matching of ligand with GPR2 receptor in mammals provides methods of use.Type: ApplicationFiled: July 2, 2001Publication date: October 31, 2002Applicant: Schering Corpration, a New Jersey corporationInventors: Wei Wang, Elizabeth R. Oldham, Hortensia Soto, Ying Liu, Susan A. Hudak, Bernhard Homey, Janine M. Morales, Sirid-Aimee Kellermann, Leslie M. McEvoy, Edward P. Bowman, Albert Zlotnik